# Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy

> **NCT06495424** · — · ACTIVE_NOT_RECRUITING · sponsor: **Averitas Pharma, Inc.** · enrollment: 144 (actual)

## Conditions studied

- Peripheral Diabetic Neuropathy
- Painful Diabetic Neuropathy

## Interventions

- **DRUG:** Capsaicin 8%

## Key facts

- **NCT ID:** NCT06495424
- **Lead sponsor:** Averitas Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-14
- **Primary completion:** 2027-03-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06495424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06495424, "Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06495424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*